Continous fentanyl infusion in newborns with hypoxic ischemic encephalopathy treated with therapeutic hypothermia: pharmacokinetics study

2024-516076-15-00 Protocol FentanylTH Human pharmacology (Phase I) - Other Authorised, recruitment pending

Status Authorised, recruitment pending · 1 EU/EEA countries · 1 sites · Protocol FentanylTH

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Authorised, recruitment pending
Participants planned 20
Countries 1
Sites 1

Infants with perinatal asphyxiation and indication to hypothermic treatment with analgo-sedation performed with fentanyl

To evaluate pharmacokinetics of Fentanyl in asphyxiated infants treated with hypothermia, in a standard regimen of Fentanyl administration.

Key facts

Sponsor
Azienda Ospedaliero Universitaria Di Modena
Participant type
Pediatric, Patients
Age range
0-17 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Nervous System Diseases [C10]
Decision date (initial)
2024-08-05
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-516076-15-00
EudraCT number
2020-000836-23

Trial design

CTIS Part I — objectives, methods, condition coding

Main objective

Scope: Safety, Pharmacokinetic

To evaluate pharmacokinetics of Fentanyl in asphyxiated infants treated with hypothermia, in a standard regimen of Fentanyl administration.

Secondary objectives 1

  1. To evaluate the safety of the Fentanyl regimen

Conditions and MedDRA coding

Infants with perinatal asphyxiation and indication to hypothermic treatment with analgo-sedation performed with fentanyl

VersionLevelCodeTermSystem organ class
21.1 LLT 10070512 Hypoxic-ischemic encephalopathy 10029205

Eligibility criteria

Principal inclusion / exclusion criteria as submitted by sponsor

Inclusion criteria 1

  1. - newborn eligible for hypothermic treatment the treatment of perinatal asphyxia - a gestational age ≥ 35 weeks and a birth weight > 1.8 kg; - with Apgar Score at 5 min ≤ 5 or with continued resuscitation at 10 min postnatal or with 1 h postnatal blood gas analysis pH<7.0 or base deficit>12 - clinical signs of encephalopathy - moderate to severe aEEG anomalies or seizures - neuroprotective treatment by controlled hypothermia <6 h postnatal life - parental written informed consent for participation in the study obtained - study analgesic treatment available

Exclusion criteria 1

  1. - Known genetic or chromosomal disorders or major malformation - No central venous line placement - No written parental consent to participate following informed consent interview

Endpoints

Primary and secondary outcome measures (English text)

Primary endpoints 1

  1. To evaluate pharmacokinetics of Fentanyl in asphyxiated infants treated with hypothermia, in a standard regimen of Fentanyl administration. Drug plasma concentrations at zero-time, within 30 min of the administration of the starting bolus, after 24-48-72-96 hours infusion will be assessed. Maximun- minimun concentration (Cmax-min) and clearance of drug will be determined.

Secondary endpoints 1

  1. To evaluate the safety of the Fentanyl regimen (load of 2 mcg/Kg of Fentanyl followed by a continuous infusion of Fentanyl at dosage of 1 mcg/kg/h for TH and heating fase) by recording drug side effect

Investigational products

Investigational medicinal products (IMPs), comparators, placebo, auxiliary

Test 1

Fentanyl Citrate

SCP1075324 · ATC

Active substance
Fentanyl Citrate
Substance synonyms
FENTANYL DIHYDROGEN CITRATE, 2-HYDROXYPROPANE-1,2,3-TRICARBOXYLIC ACID, N-(1-PHENETHYL-4-PIPERIDYL)-N-PHENYL-PROPANAMIDE
Route of administration
INTRAVENOUS
Authorisation status
Authorised
ATC code
N01AH01 — FENTANYL
Marketing authorisation
-
Paediatric formulation
No
Orphan designation
No
Modified vs. Marketing Authorisation
No

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Azienda Ospedaliero Universitaria Di Modena

Sponsor organisation
Azienda Ospedaliero Universitaria Di Modena
Address
Largo Del Pozzo 71
City
Modena
Postcode
41124
Country
Italy

Scientific contact point

Organisation
Azienda Ospedaliero Universitaria Di Modena
Contact name
Licia Lugli

Public contact point

Organisation
Azienda Ospedaliero Universitaria Di Modena
Contact name
Licia Lugli

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Italy Authorised, recruitment pending 20 1
Rest of world 0

Investigational sites

Italy

1 site · Authorised, recruitment pending
Azienda Ospedaliero Universitaria Di Modena
Materno Infantile, Largo Del Pozzo 71, 41124, Modena

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-07-02 Italy Acceptable
2024-07-29
2024-08-05